Ariceum Therapeutics GmbH is a rapidly growing clinical-stage company focused on developing next-generation radiopharmaceutical cancer therapeutics and diagnostics. Our pipeline includes Lutetium-177 Satoreotide (SSO110), paired with Gallium-68 Satoreotide (SS0120), for the combined diagnosis and targeted radionuclide treatment of neuroendocrine cancers. Additionally, our novel therapeutic product, Iodine-123 ATT001, a radiolabeled PARP inhibitor, is in a Phase 1 clinical trial for re...